Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NexMed has developed a room temperature formulation of Alprox-TD, its proprietary topical treatment for erectile dysfunction, and announced plans to move forward with a new regulatory strategy for the drug candidate.
Subscribe to our email newsletter
Alprox-TD is based on NexMed’s proprietary NexACT drug delivery technology, which the company has also used to develop a number of experimental medicines, including treatments for nail fungus and sexual disorders.
“This new technical development will further enhance our product’s commercialization prospects,” stated Daniel Frank, senior director of pharmaceutical operations at NexMed. “The ease of distributing a room temperature formulation of Alprox-TD, compared to a refrigerated formulation, will be of great interest and importance to potential pharmaceutical partners with whom we are currently in discussion.”
NexMed’s new regulatory strategy for Alprox-TD, meanwhile, will include the filing of a new drug application in the US and a marketing authorization application in Europe during the first half of 2007.